Nektar Therapeutics
NKTR
$56.23
-$0.39-0.69%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -50.19% | 84.96% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -50.19% | 84.96% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -50.19% | 84.96% | |||
| SG&A Expenses | 20.15% | -30.40% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.10% | -5.60% | |||
| Operating Income | -100.41% | 39.46% | |||
| Income Before Tax | -24.39% | -1.39% | |||
| Income Tax Expenses | 106.45% | 193.94% | |||
| Earnings from Continuing Operations | -24.46% | -1.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -24.46% | -1.57% | |||
| EBIT | -100.41% | 39.46% | |||
| EBITDA | -101.62% | 39.69% | |||
| EPS Basic | -2.12% | 5.19% | |||
| Normalized Basic EPS | -31.54% | 27.59% | |||
| EPS Diluted | -2.12% | 5.19% | |||
| Normalized Diluted EPS | -31.54% | 27.59% | |||
| Average Basic Shares Outstanding | 21.87% | 7.13% | |||
| Average Diluted Shares Outstanding | 21.87% | 7.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||